Please login to the form below
No-deal
This page shows the latest No-deal news and features for those working in and with pharma, biotech and healthcare.
Roche expands infectious disease test portfolio
While no financial details of the deal have been announced, Roche has agreed to acquire 100% of the outstanding shares of the TIB Molbiol Group, a transaction expected to close in ... Infectious disease remains a high priority for Roche which, in March,
Latest news
-
COVID-19 delays Pfizer, Mylan’s generics merger and spin-out
Meanwhile, Mylan's meeting of shareholders to approve the deal is also being moved back from 27 April to 30 June. ... There are no changes to the terms of the deal, which will see Pfizer acquire Mylan, merge it with Upjohn and spin out the combined
-
It’s Brexit day – now comes the really hard stuff
Justice. Failure to agree a deal would of course leave the spectre of a no-deal exit from the bloc on the table, something the industry wants to avoid at all ... Michael Warren, who covers Brexit and trade issues for the BIA, said that there’s been
-
EU group calls for 'targeted actions' to mitigate impact of Brexit
Leaving the EU without a deal covering professional qualifications would break the mechanism for mutual recognition. ... The UK addressed that scenario in its no-deal planning, stating that it would not be “appropriate to retain provisions based on a
-
Another day, another Brexit delay – so what happens now?
The official line is Labour wants to defer any election until a no-deal Brexit has effectively been ruled out. ... Once again, the proviso is that the withdrawal agreement bill is shelved and the threat of a no-deal Brexit removed.
-
UK rations AZ’s paediatric flu vaccine after delivery delays
In August, NHS leaders warned that a no-deal Brexit would make delays in the flu vaccine supply this year more likely, and there has been a rush for all producers
More from news
Approximately 3 fully matching, plus 134 partially matching documents found.
Latest Intelligence
-
Setting up for success in a post-Brexit, post-pandemic Britain
mention Brexit deal negotiations going down to the wire, we have truly found ourselves in an unprecedented situation. ... Fortunately, we now have a deal in place, which has helped alleviate the uncertainty attached to a ‘no deal’ scenario.
-
Integrating competitive intelligence into business development, licensing and M&A strategy
In summary, all parties need competitive intelligence when seeking to find the right partner for a potential deal. ... By this it is safe to conclude that no BD&L or M&A deal should proceed without an abundance of CI integrated into the process.
-
The science of the deal
The variables of these asymmetric R&D deals are so numerous and so diverse that there is no single, optimal deal structure, only a best deal structure for any given situation. ... So,. the question arises: what’s the best way to craft a deal?
-
Case study: Leading by example
how the sector should respond publicly to the threat of a ‘no deal’ scenario. ... The company was keen to reassure patients about the steps it has taken to keep a continuity of medical supplies in a ‘no deal’ scenario.
-
The mission matters
No leader or leadership team has the technical knowledge to fully understand, let alone micromanage, such a diverse and expert group. ... No other industry has the same sort of bargain with society, which has been beneficial to both sides.
More from intelligence
Approximately 0 fully matching, plus 29 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
PMHub
Research Partnership
Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
